Handelsbanken Fonder Ab Madrigal Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $24.3 Billion
- Q1 2025
A detailed history of Handelsbanken Fonder Ab transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 4,800 shares of MDGL stock, worth $1.55 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,800
Previous 32,800
85.37%
Holding current value
$1.55 Million
Previous $10.1 Million
84.29%
% of portfolio
0.01%
Previous 0.04%
Shares
10 transactions
Others Institutions Holding MDGL
# of Institutions
342Shares Held
22.2MCall Options Held
960KPut Options Held
940K-
Janus Henderson Group PLC London, X02.21MShares$712 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$658 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$654 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$643 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$636 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.51B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...